



PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 7 October 2004



THE PATENT OFFICE

26 SEP 2003

NEWPORT

26SEP03 E840165-1 D02554
P01/7700 0.00 0322552.1

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

 Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference 101223-1 GB

2. Patent application number
(The Patent Office will fill in this part)

0322552.1

26 SEP 2003

3. Full name, address and postcode of the or of
each applicant (underline all surnames)
 AstraZeneca UK Limited
15 Stanhope Gate
London
W1K 1LN

Patents ADP number (if you know it)

7896467002

If the applicant is a corporate body, give the
country/state of its incorporation

England

4. Title of the invention

THERAPEUTIC TREATMENT

5. Name of your agent (if you have one)

Kevin BILL

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

 AstraZeneca
Global Intellectual Property
PO Box 272
Mereside, Alderley Park
Macclesfield,
Cheshire SK10 4GR

Patents ADP number (if you know it)

8179707001

6. If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and (if you know it) the or
each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day / month / year)
 8. Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:
 a) any applicant named in part 3 is not an inventor, or
 b) there is an inventor who is not named as an
applicant, or
 c) any named applicant is a corporate body.
 See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 10

Claim(s) 2

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date 25.09.03

12. Name and daytime telephone number of person to contact in the United Kingdom

Jennifer Bennett - 01625 230148

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

THERAPEUTIC TREATMENT

The present invention relates to a combination comprising candesartan and rosuvastatin.

5 The present invention further relates to pharmaceutical compositions comprising the combination mentioned hereinbefore. The present invention further relates to the use of a combination mentioned hereinbefore in the prevention or treatment of atherosclerosis.

10 Atherosclerosis is a condition mediated by complex pathological processes which result in irregularly distributed lipid deposits in the arteries and is a major contributory factor to coronary heart disease. A reduction in atherosclerosis is therefore a major target for 15 reducing the number of cardiovascular events for example, myocardial infarction, worsening of angina, cardiac arrest, stroke, congestive heart failure and cardiovascular death.

Dyslipidemia, particularly increased plasma level of low-density lipoprotein (LDL) is one of the major risk factors in atherosclerosis. Clinical studies have demonstrated that 15 reducing plasma LDL level with 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, commonly known as statins, results in a lower risk of cardiovascular events.

20 Activation of the renin-angiotensin system (RAS) may be considered another important risk factor in atherosclerosis. Activation of RAS with the formation of angiotensin (II) (A (II)) and the activation of A (II) receptors have been implicated in atherogenesis, plaque rupture, myocardial ischemic dysfunction and congestive heart failure (Singh and Mehta, Arch Intern Med, 2003, vol 163, 1296-1304).

25 We have surprisingly found that the combination of the A(II) antagonist candesartan and the HMG CoA reductase inhibitor rosuvastatin has a synergistic effect in the reduction of atherosclerosis. This synergistic effect appears to arise from synergistic inhibition of expression of a number of inflammatory mediators involved in the RAS (for example CD40 and metalloproteinases) and/or inhibition of the expression of the receptor LOX-1 (which is a receptor for oxidised LDL on endothelial cells). The synergistic effect provides strong evidence for cross-talk between the RAS and dyslipidemia in atherogenesis.

30 In one aspect of the invention is provided a combination comprising candesartan, or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically acceptable salt thereof, for the prevention or treatment of atherosclerosis.

In one aspect of the invention is provided a combination comprising candesartan, or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically acceptable salt thereof, for the prevention of cardiovascular events.

Such a combination may also be useful in the treatment or prevention of other diseases 5 associated with these mediators, for example in inflammatory diseases or conditions, such as ischemia-reperfusion injury (to the heart, brain, kidneys, lungs and liver), radiation-induced injury, burn injury and peripheral vascular disease,

Candesartan may suitably be in the form of candesartan, or in the pro-drug form 10 candesartan cilexetil. These forms may be formulated with a further agent such as a diuretic such as hydrochlorothiazide (for example, as marketed as 'Atacand Plus').

Where herein candesartan is referred to, this includes both candesartan and candesartan cilexetil.

Preferably the calcium salt of rosuvastatin, which may be referred to as rosuvastatin calcium, is used in the various aspects of the present invention.

15 Herein, where the term "combination" is used it is to be understood that this refers to simultaneous, separate or sequential administration. In one aspect of the invention "combination" refers to simultaneous administration. In another aspect of the invention "combination" refers to separate administration. In a further aspect of the invention "combination" refers to sequential administration. Where the administration is sequential or 20 separate, the delay in administering the second component should be such that both agents are present in the body so as to produce the synergistic effect of the combination.

In a further aspect of the invention is provided a pharmaceutical composition which 25 comprises candesartan, or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the prevention or treatment of atherosclerosis.

In a further aspect of the invention is provided a pharmaceutical composition which comprises candesartan, or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the prevention or reduction of risk of cardiovascular events.

30 The compositions described herein may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream, for

rectal administration for example as a suppository or the route of administration may be by direct injection into the tumour or by regional delivery or by local delivery. In other embodiments of the present invention the compounds of the combination treatment may be delivered endoscopically, intratracheally, intralesionally, percutaneously, intravenously, 5 subcutaneously, intraperitoneally or intratumourally. In general the compositions described herein may be prepared in a conventional manner using conventional excipients or carriers that are well known in the art.

Suitable pharmaceutically-acceptable excipients or carriers for a tablet formulation include, for example, inert excipients such as lactose, sodium carbonate, calcium phosphate or 10 calcium carbonate, granulating and disintegrating agents such as corn starch or alginic acid; binding agents such as gelatin or starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl 4-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to 15 modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid excipient, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is 20 mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

Candesartan is commercially available as 'Atacand' and 'Atacand Plus'. Rosuvastatin calcium is commercially available as 'Crestor'. Suitable formulations for the present invention include those which are commercially available.

Suitable dosages of each component of the combination are those of the marketed 25 commercial products. Alternatively, the synergy between the components may allow a lower dosage of one or both components to be used. For example, a dose of 4mg, 8mg, 16mg, 32mg, or up to 160mg of candesartan in combination with a dose of 80mg, 40mg, 20mg, 10mg, 5mg or 2.5mg of rosuvastatin may be used. It will be understood that any one of the doses of candesartan may be combined with any suitable dose of rosuvastatin.

30 It will be appreciated that the pharmaceutical composition according to the present invention includes a composition comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically-acceptable excipient or carrier. Such a composition, for example in a single

oral formulation conveniently provides the therapeutic combination product of the invention for simultaneous administration in the prevention or treatment of atherosclerosis.

Preferably the two components of the combination are both administered orally.

Preferably the two components of the combination are administered as a single oral 5 formulation.

Preferably the combination is formulated for once-a-day dosing.

The dosages and schedules described hereinbefore may be varied according to the particular disease state and the overall condition of the patient. For example, it may be necessary or desirable to reduce the above-mentioned doses of the components of the 10 combination treatment in order to reduce toxicity. Dosages and schedules may also vary if, in addition to a combination treatment of the present invention, one or more additional chemotherapeutic agents are used. Scheduling can be determined by the practitioner who is treating any particular patient using his professional skill and knowledge.

A pharmaceutical composition according to the present invention also includes 15 separate compositions comprising a first composition comprising candesartan or a pharmaceutically acceptable salt thereof and a pharmaceutically-acceptable excipient or carrier, and a second composition comprising rosuvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically-acceptable excipient or carrier. Such a composition conveniently provides the therapeutic combination of the invention for sequential or separate 20 administration in the synergistic prevention or treatment of atherosclerosis but the separate compositions may also be administered simultaneously.

In another aspect of the invention is provided a combination comprising candesartan, or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically acceptable salt thereof, for use as a medicament for the prevention or treatment of 25 atherosclerosis.

In another aspect of the invention is provided a combination comprising candesartan, or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically acceptable salt thereof, for use as a medicament for the prevention of cardiovascular events.

In another aspect of the invention is provided a combination comprising candesartan, 30 or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament.

In another aspect of the invention is provided a combination comprising candesartan, or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically

acceptable salt thereof, for use in the manufacture of a medicament for the prevention or treatment of atherosclerosis.

5 In another aspect of the invention is provided a combination comprising candesartan, or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for the prevention of cardiovascular events.

10 In a further aspect of the invention is provided a method of preventing or treating atherosclerosis in a warm-blooded animal, such as man, which comprises administering a combination of candesartan, or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically acceptable salt thereof.

15 In a further aspect of the invention is provided a method of preventing cardiovascular events in a warm-blooded animal, such as man, which comprises administering a combination of candesartan, or a pharmaceutically acceptable salt thereof, and rosuvastatin, or a pharmaceutically acceptable salt thereof.

20 According to a further aspect of the present invention there is provided a kit comprising a combination of candesartan or a pharmaceutically acceptable salt thereof, and rosuvastatin; or a pharmaceutically acceptable salt thereof, optionally with instructions for use in the prevention or treatment of atherosclerosis.

25 According to a further aspect of the present invention there is provided a kit comprising:

- a) candesartan in a first unit dosage form;
- b) rosuvastatin; in a second unit dosage form; and
- c) container means for containing said first and second dosage forms; and optionally
- d) with instructions for use in the prevention or treatment of atherosclerosis.

30 According another aspect of the present invention there is provided a method of inhibiting expression of CD40 and/or metalloproteinases (MMPs) by administering a combination of candesartan, or a pharmaceutically acceptable salt thereof and rosuvastatin, or a pharmaceutically acceptable salt thereof.

35 According another aspect of the present invention there is provided a method of treating atherosclerotic patients by inhibition of expression of CD40 and/or metalloproteinases (MMPs) by administering an amount of a combination of candesartan, or a pharmaceutically acceptable salt thereof and rosuvastatin, or a pharmaceutically acceptable salt thereof suitable for inhibition of expression of CD40 and/or metalloproteinases (MMPs).

According another aspect of the present invention there is provided a method of inhibiting expression of LOX-1 by administering a combination of candesartan, or a pharmaceutically acceptable salt thereof and rosuvastatin, or a pharmaceutically acceptable salt thereof.

5 According another aspect of the present invention there is provided a method of treating atherosclerotic patients by inhibition of expression of LOX-1 by administering an amount of a combination of candesartan, or a pharmaceutically acceptable salt thereof and rosuvastatin, or a pharmaceutically acceptable salt thereof suitable for inhibition of expression of LOX-1.

10

Materials and Methods

Animal Model

Five pairs of C57BL/6J mice and three pairs of homozygous apo-E knockout mice (on C57BL/6J background) were obtained from Jackson Laboratories (Bar Harbor, ME). They 15 were bred by brother-sister mating and housed in a room lit from 6:00 AM to 6:00 PM and kept at 21°C. The C57BL/6J mice (n=10) were continued on regular diet for the entire study period. The apo-E knockout mice were divided into four groups. Group1 (n=10) animals were given high-cholesterol diet (1% cholesterol) alone for 12 weeks since the age of 6 weeks; Group2 (n=10) animals were given high-cholesterol diet with candesartan (1mg/kg/d) for 12 weeks since the age of 6 weeks; Group3 (n=10) animals were given high-cholesterol diet with the rosuvastatin (1mg/kg/d) for 12 weeks since the age of 6 weeks; Group 4 (n=10) were given high-cholesterol diet with candesartan (1mg/kg/d) and rosuvastatin (1mg/kg/d) for 12 weeks since the age of 6 weeks.

20 At the end of 12-week-treatment, the mice were sacrificed and subject to studies described below. All experimental procedures were performed in accordance with protocols approved by the Institutional Animal Care and Usage Committee of University of Arkansas for Medical Sciences.

Quantitative Analysis of Atherosclerotic Plaques

At the end of 12-week-treatment, 5 mice from each group were euthanized and the 30 aortas were separated from surrounding tissues. After removal of the adventitial fat tissue, the aortas were opened longitudinally from the aorta arch to the iliac bifurcation, and fixed in

10% formalin for 24 hours. Then the aortas were rinsed in 70% alcohol briefly, stained with Sudan IV solution for 15 minutes, differentiated in 80% alcohol for 20 minutes and washed in running water for 1 hour (25). The aortas were mounted and their pictures were taken with a camera connected to a dissection microscope. The images were analyzed by soft ware (Image 5 Pro Plus, Media Cybernetics) as described previously (26).

RNA Preparation and Analysis by RT-PCR

At the end of 12-week-treatment, 5 mice from each group were euthanized and the aortas (from aorta arch to iliac bifurcation) were separated from surrounding tissues and stored on dry ice. Each aorta was cut into four segments, two of which were used to extract 10 total RNA with the single-step acid-guanidinium thiocyanate-phenol-chloroform method as described earlier (27). One microgram of total RNA was reverse transcribed into cDNA with oligo-dT (Promega, Madison, WI, U.S.A.) and Maloney murine leukemia virus (M-MLV) reverse transcription (Promega) at 42°C for 1 hour. Two microliters of reverse transcription (RT) material was amplified with Taq DNA polymerase (Promega) and a primer pair specific 15 to mouse LOX-1, CD40 or MMPs (MMP-1, -2, -9). For mouse LOX-1, forward primer: 5'-TTACTCTCCATGGTGGTGCC-3', reverse primer: 5'-AGCTTCTTCTGCTTGTGCC-3' were used. 30 cycles of polymerase chain reaction (PCR) were performed at 94°C for 40 seconds (denaturation), 55°C for 1 minute (annealing), and 72°C for 1 minute (extension). The size of polymerase chain reaction (PCR) product was 193 base pairs. For mouse CD40, 20 forward primer 5'-GTTAAAGTCCCGGATGCGA-3' and reverse primer 5'-CTCAAGGCTATGCTGTCTGT-3' were used. 35 cycles of polymerase chain reaction (PCR) were performed at 94°C for 1 minute (denaturation), 55°C for 1 minute (annealing), and 72°C for 1 minute (extension). The size of PCR product was 408 base pairs. For mouse MMP-1, forward primer 5'-GGACTCTCCCATTCTTAATGA T-3' and reverse primer 5'-CCTCTTCTGGATAACATCATCA AC-3' were used. For mouse MMP-2, forward primer 5'-ATCAAGGGATCCAGGAGC-3' and reverse primer 5'-GCAGCGATGAAGATGATAG-3' were used. For mouse MMP-9, forward primer 5'-AGTTGGTGTGCGGGAGCAC-3' and reverse primer 5'-TACATGAGCGCTTCCGGCAC-3' were used. For all MMPs, 35 cycles of PCR were 25 performed at 94°C for 1 minute (denaturation), 58°C for 1 minute (annealing), and 75°C for 1 minute (extension). The sizes of PCR product were 627, 718 and 753 base pairs, respectively. A primer pair specific to mouse β -actin was used as housekeeping gene (forward primer: 5'-TTCTACAATGAGCTGCGTTG-3', reverse primer: 5'-CACTGTGTTGGCATAGAGGTC-

3°). 30 cycles were used at 94°C for 30 seconds (denaturation), 55°C for 1 minute (annealing), and 72°C for 1 minute (extension). PCR product was 560 base pairs. The reverse transcription PCR (RT-PCR)-amplified sample was visualized on 1.5% agarose gel using ethidium bromide.

5 Protein Preparation and Analysis by Western Blot

Each mouse aorta was cut into four segments. Two of them were used to extract RNA, and the remaining two were used to extract protein as described previously (14). In brief, the aortic tissues were homogenized and lysed in lysis buffer, then centrifuged at 4000 rpm for 10 minutes at 4°C. The lysate proteins from aortas (20 µg/lane) were separated by 10% SDS-PAGE, and transferred to nitrocellulose membranes. After incubation in blocking solution (5% non-fat milk, Sigma), membranes were incubated with 1:750 dilution monoclonal antibody to mouse LOX-1 for overnight at 4°C. Membranes were washed and then incubated with 1:5000 dilution specific secondary antibody (Amersham Life Science) for 2 hours at room temperature, and the membranes were washed and detected with the ECL system (Amersham Life Science). The relative intensities of protein bands were analyzed by Scan-gel-it software (24).

Data Analysis

All data represent mean of duplicate samples. Data are presented as mean \pm SD. Statistical significance was determined in multiple comparisons among independent groups of 20 data in which ANOVA and the F test indicated the presence of significant differences. A P value <0.05 was considered significant.

Results

The synergistic anti-atherosclerotic effect of candesartan and rosuvastatin

25 Compared with the control mice (C57BL/6J mice fed regular diet), the apo-E knockout mice fed high-cholesterol diet developed extensive atherosclerosis ($P<0.01$ vs control mice). Although both candesartan and rosuvastatin alone decreased the extent of atherosclerosis ($p<0.05$ vs high-cholesterol diet alone), the combination reduced atherosclerosis to a much greater extent ($P<0.05$ vs candesartan or rosuvastatin alone plus 30 high-cholesterol diet). Figure 1 shows results of representative experiments and the extent of atherosclerosis (mean \pm SD) in different groups of animals.

Candessartan and rosuvastatin alone decreased atherosclerosis by about 35% and 25% respectively. The combination reduced atherosclerosis by 70%, demonstrating a synergistic effect.

The synergistic effect of candesartan and rosuvastatin on LOX-1 expression

5 In the control C57BL/6J mice, the expression of LOX-1 (mRNA and protein) was low (Figure 2). In contrast, LOX-1 expression (mRNA and protein) was markedly increased by high-cholesterol diet in apo-E knockout mice ($P<0.01$ vs control mice). Both candesartan and rosuvastatin alone decreased the LOX-1 expression (mRNA and protein), albeit modestly ($P<0.05$ vs high-cholesterol diet alone). The combination of candesartan and rosuvastatin had 10 a dramatic inhibitory effect on the up-regulation of LOX-1 (mRNA and protein) in apo-E knockout mice ($P<0.01$ vs high-cholesterol diet alone).


The synergistic effect of candesartan and rosuvastatin on CD40 expression

15 Compared with the expression in control C57BL/6J mice, CD40 expression (mRNA and protein) was markedly increased in apo-E knockout mice fed a high-cholesterol diet in ($P<0.01$ vs control mice). Although candesartan and rosuvastatin treatment alone slightly decreased CD40 expression ($P<0.05$ vs high-cholesterol diet alone), the combination of candesartan and rosuvastatin had a dramatic inhibitory effect on the up-regulation of CD40 (mRNA and protein) in the apo-E knockout mice ($P<0.01$ vs high-cholesterol diet alone).

20 The synergistic effect of candesartan and rosuvastatin on MMPs expression

Compared with the expression in control C57BL/6J mice, MMP-1, -2 and -9 expression (mRNA and protein) was markedly increased in high-cholesterol diet-fed apo-E knockout mice ($P<0.01$ vs control mice). Both candesartan and rosuvastatin alone decreased 25 MMP-1, -2 and -9 expression (mRNA and protein), albeit modestly ($P<0.05$ vs high-cholesterol diet alone). The combination of candesartan and rosuvastatin had a dramatic inhibitory effect on their expression ($P<0.01$ vs high-cholesterol diet alone).

Figure 1



Claims

1. A combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof for prevention or treatment of atherosclerosis.

5

2. A pharmaceutical composition which comprises a combination as claimed in Claim 1 in association with a pharmaceutically acceptable diluent or carrier for use in the prevention or treatment of atherosclerosis.

10 3. A pharmaceutical composition which comprises a combination as claimed in Claim 1, in association with a pharmaceutically acceptable diluent or carrier for use in the prevention of cardiovascular events.

15 4. A combination as claimed in Claim 1 for use in the manufacture of a medicament for the prevention or treatment of atherosclerosis.

5. A combination as claimed in Claim 1 for use in the manufacture of a medicament for the prevention of cardiovascular events.

20 6. A combination as claimed in Claim 1 for use as a medicament for the prevention or treatment of atherosclerosis.

7. A combination as claimed in Claim 1 for use as a medicament for prevention of cardiovascular events.

25

8. A method of preventing or treating atherosclerosis in a warm-blooded animal, such as man, which comprises administering a combination as claimed in Claim 1.

9. A method of preventing cardiovascular events in a warm-blooded animal, such as man, which comprises administering a combination as claimed in Claim 1.

30 10. A kit comprising a combination as claimed in Claim 1; optionally with instructions for use in the prevention or treatment of atherosclerosis.

11. A combination as claimed in Claim 1 wherein candesartan is in the form of candesartan cilexetil.

BEST AVAILABLE COPY

PCT/GB2004/004120



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.